Canertinib is a potent and selective inhibitor of tyrosine residue phosphorylation of EGFR, blocking signal transgression and ceasing angiogenisis. Canertinib displays an IC50 = 1.5nM. Additionally, Canertinib's action in inhibiting EGFR increases apoptosis in cancerous cell lines in a titratable fashion.
Li, D., et al.: Oncogene, 27, 4702 (2008), Brown, A., et al.: Toxicol. Pathol., 36, 410 (2008), Chen, H., et al.: Chem. Biol. Drug Design, 71, 434 (2008),
See how others have used Canertinib. Click on the entry to view the PubMed entry .
PMID: # 30462579 Paatero, I.|Veikkolainen, V.|Mäenpää, M.|Schmelzer, E.|Belting, HG.|Pelliniemi, LJ.|Elenius, K.| et al. 2019. Mol. Biol. Cell. 30: 209-218.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.